Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors at 3 institutions in 2 countries.
Jiayu Xu *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Yuexiu Zhang *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-3948-1425
Panke Qu *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Mohamed M Shamseldin *Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.
Sung J Yoo *Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-0892-2718
Jack Misny *Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
Ilada ThongpanCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.
Mahesh KcCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.ORCID 0000-0002-5177-9566
Jesse M HallDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.
John P EvansDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0001-8644-5825
Mostafa EltobgyDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-4056-7429
Mijia LuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Chengjin YeDepartment of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227.ORCID 0000-0002-1934-9494
Michelle ChambleeDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Xueya LiangDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.
Luis Martinez-SobridoDepartment of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227.ORCID 0000-0001-7084-0804
Amal O AmerDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.ORCID 0000-0003-4487-7536
Jacob S YountDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.
Prosper N BoyakaDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0001-6857-9088
Mark E PeeplesCenter for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205.ORCID 0000-0002-4582-317X
Shan-Lu LiuDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0003-1620-3817
Purnima DubeyDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-5454-8421
Jianrong LiDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-7130-1084
The Ohio State University · USNationwide Children's Hospital · USTexas Biomedical Research Institute · US
Funding
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinolsU19AI142731 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI EBRIGHT, RICHARD H. · 2019 to 2023
$33.9M
Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4M
Project 3: Dr. LiP01AI112524 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI PEEPLES, MARK E., RAMILO, OCTAVIO · 2015 to 2019
$6.8M
Mechanisms of innate resistance to virus infectionsR01AI130110 · NIAID · OHIO STATE UNIVERSITY · PI Jacob Yount · 2017 to 2026
$4.3M
Messenger RNA Capping and Methylation in PneumovirusesR01AI090060 · NIAID · OHIO STATE UNIVERSITY · PI LI, JIANRONG · 2011 to 2023
$4.0M
Identification of novel immunogenic proteins from Bordetella pertussisR01AI153829 · NIAID · OHIO STATE UNIVERSITY · PI DEORA, RAJENDAR K, DUBEY, PURNIMA · 2021 to 2025
$3.8M
Host Responses to the Pore-Forming Toxin Listeriolysin OR01AI157205 · NIAID · OHIO STATE UNIVERSITY · PI AMER, AMAL O, BOYAKA, PROSPER N · 2021 to 2025
$3.2M
Targeting myeloid cells for regulation of alum-based immunityR01AI145144 · NIAID · OHIO STATE UNIVERSITY · PI BOYAKA, PROSPER N · 2020 to 2024
$3.1M
Mechanisms of lung and cardiac pathology in SARS-CoV-2 infectionsR01HL168501 · NHLBI · OHIO STATE UNIVERSITY · PI Amal O Amer, Jacob Yount · 2023 to 2026
$2.9M
Protein therapy to treat virus induced cardiopulmonary injuryR01HL157215 · NHLBI · UNIVERSITY OF VIRGINIA · PI CAI, CHUANXI, MA, JIANJIE · 2022 to 2025
$2.7M
Mechanistic characterization of a new master regulator of cardiac virus infectionsR01HL154001 · NHLBI · OHIO STATE UNIVERSITY · PI ACCORNERO, FEDERICA, YOUNT, JACOB · 2020 to 2023
$2.3M
Interdisciplinary Program in Microbe-Host BiologyT32AI165391 · NIAID · OHIO STATE UNIVERSITY · PI RAJENDAR K DEORA, Daniel J Wozniak · 2022 to 2026
As SARS-CoV-2 variants of concern (VoCs) that evade immunity continue to emerge, next-generation adaptable COVID-19 vaccines which protect the respiratory tract and provide broader, more effective, and durable protection are urgently needed. Here, we have developed one such approach, a highly efficacious, intranasally delivered, trivalent measles-mumps-SARS-CoV-2 spike (S) protein (MMS) vaccine candidate that induces robust systemic and mucosal immunity with broad protection. This vaccine candidate is based on three components of the MMR vaccine, a measles virus Edmonston and the two mumps virus strains [Jeryl Lynn 1 (JL1) and JL2] that are known to provide safe, effective, and long-lasting protective immunity. The six proline-stabilized prefusion S protein (preS-6P) genes for ancestral SARS-CoV-2 WA1 and two important SARS-CoV-2 VoCs (Delta and Omicron BA.1) were each inserted into one of these three viruses which were then combined into a trivalent "MMS" candidate vaccine. Intranasal immunization of MMS in IFNAR1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern. · full record | OpenQuestion